Previous Article | Next Article 
Mol Cell Biol, March 1998, p. 1489-1497, Vol. 18, No. 3
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
EWS, but Not EWS-FLI-1, Is Associated with Both
TFIID and RNA Polymerase II: Interactions between Two Members of the
TET Family, EWS and hTAFII68, and Subunits of TFIID and RNA
Polymerase II Complexes
Anne
Bertolotti,1
Thomas
Melot,2
Joël
Acker,1
Marc
Vigneron,1
Olivier
Delattre,2 and
Laszlo
Tora1,*
Institut de Génétique et de
Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, F-67404
Illkirch Cedex, C.U. de Strasbourg,1 and
Institut Curie, Unité 434 de l'INSERM, 75248 Paris Cedex
05,2 France
Received 4 September 1997/Returned for modification 14 October
1997/Accepted 24 November 1997
 |
ABSTRACT |
The t(11;22) chromosomal translocation specifically linked to Ewing
sarcoma and primitive neuroectodermal tumor results in a chimeric
molecule fusing the amino-terminus-encoding region of the
EWS gene to the carboxyl-terminal DNA-binding domain
encoded by the FLI-1 gene. As the function of the protein
encoded by the EWS gene remains unknown, we investigated
the putative role of EWS in RNA polymerase II (Pol II) transcription by
comparing its activity with that of its structural homolog,
hTAFII68. We demonstrate that a portion of EWS is able to
associate with the basal transcription factor TFIID, which is composed
of the TATA-binding protein (TBP) and TBP-associated factors
(TAFIIs). In vitro binding studies revealed that both EWS
and hTAFII68 interact with the same TFIID subunits,
suggesting that the presence of EWS and that of hTAFII68 in
the same TFIID complex may be mutually exclusive. Moreover, EWS is not
exclusively associated with TFIID but, similarly to hTAFII68, is also associated with the Pol II complex. The
subunits of Pol II that interact with EWS and hTAFII68 have
been identified, confirming the association with the polymerase. In
contrast to EWS, the tumorigenic EWS-FLI-1 fusion protein is not
associated with either TFIID or Pol II in Ewing cell nuclear extracts.
These observations suggest that EWS and EWS-FLI-1 may play different roles in Pol II transcription.
 |
INTRODUCTION |
Structural alteration or aberrant
expression of transcription factors is often a critical event in
tumorigenic transformation (13, 19, 22). Karyotypic analysis
has revealed a tumor-specific t(11;22)(q24;q12) chromosomal
translocation in 86% of both Ewing sarcoma and primitive
neuroectodermal tumor, suggesting that the product of this
rearrangement is involved in the formation of these malignancies
(34). This chromosomal translocation fuses the
EWS gene on chromosome 22 to the FLI-1 gene on
chromosome 11 (8). EWS is a protein with unknown function
containing an RNA-binding motif and an activation domain(s) (18,
24, 25). In the EWS-FLI-1 fusion protein, the RNA-binding motif
containing the C-terminal half of EWS is replaced by the DNA-binding
domain (DBD) of the FLI-1 protein. FLI-1 is a member of the ETS family of transcription factors which activate specific target genes by
binding to their cognate DNA sequences through their DNA-binding regions, usually located at their carboxyl termini (2, 37). The replacement of the native transcription activation domain(s) of
FLI-1 by the N-terminal region of EWS converts the nontransforming activator, FLI-1, into a transforming protein with new transcriptional activation potential. In the EWS-FLI-1 fusion protein, both the N-terminal domain of EWS and the DBD of FLI-1 are necessary for the
transforming activity (20). Recently, the EWS
gene was also shown to be involved in tumorigenesis by chromosomal
translocation with other genes encoding either other members of the ETS
family (Erg, ETV1, E1A-F, and FEV) or other transcription factors,
including ATF-1, WT1, and the nuclear orphan receptor TEC1 (16,
17, 27, 35).
The gene encoding human TLS/FUS, a protein that is highly similar to
EWS, has also been implicated in human sarcomas induced by chromosomal
translocations (7, 30). In mixoid liposarcoma, the t(12;16)
translocation fuses the TLS/FUS gene to that encoding the
transcription factor CHOP. The function of the intact TLS/FUS protein
is also unknown. Like EWS, it contains an RNA-binding motif and an
activation domain. CHOP, a member of the C/EBP family of transcription
factors, is expressed usually in response to various cellular stresses
and can induce growth arrest. It has been demonstrated that the fusion
of the N-terminal portion of either EWS or TLS/FUS to either the DBD
(FLI-1) or the dimerization domain (CHOP) of a given transcription
factor leads to tumorigenic transformation (39). These
results suggest that the N-terminal domains of these sarcoma-associated
proteins have an important and functionally similar function in the
transformation of the oncogenic cells.
Recently, we have identified and characterized a novel transcription
factor, hTAFII68, that shows extensive sequence similarity with the sarcoma-associated proteins EWS and TLS/FUS (3).
Like EWS and TLS/FUS, hTAFII68 contains a consensus
RNA-binding domain (RNP-CS) which allows it to bind not only RNA but
also single-stranded DNA (ssDNA). hTAFII68 was identified
on the basis of its substoichiometric association with a distinct TFIID
subpopulation. TFIID is a multiprotein complex composed of the
TATA-binding protein (TBP) and TBP-associated factors
(TAFIIs) and is the factor that nucleates preinitiation complex formation on protein-coding genes (31). Antibodies
raised against hTAFII68 coimmunoprecipitate a fraction of
TFIID, and anti-TBP or anti-TAFII100 monoclonal antibodies
(MAbs) coimmunopurify hTAFII68. Moreover,
hTAFII68 is associated with another multiprotein complex,
the human RNA polymerase II (Pol II) complex. Interestingly, hTAFII68 is able to enter into the preinitiation complex
together with Pol II, suggesting that hTAFII68 has a role
in transcription initiation and/or elongation. Like
hTAFII68, TLS/FUS is associated with a subpopulation of
TFIID complexes that are chromatographically distinct and
functionally different from those containing hTAFII68 (3, 5, 15). These experiments strongly suggested that hTAFII68 and TLS/FUS play an important role in the cross
talk between various components of the basal transcription machinery and that they may function by linking transcription initiation and
elongation.
Recently, a Drosophila protein, termed Cabeza
(33) or SARFH (14), that has high homology to
TLS/FUS and EWS has been described. TLS/FUS, EWS, hTAFII68,
and Cabeza all have particularly conserved RNA-binding motifs that
deviate from the organization of such domains commonly found in most
RNA-binding proteins. Thus, TLS/FUS, EWS, hTAFII68, and
Cabeza all belong to a new subfamily of RNP-CS-containing proteins that
we have called the TET family (3). TET family members all
contain an acidic residue at the second position and a threonine in the
fourth position of the RNP1 domain of their RNP-CS instead of
hydrophobic residues found in most other RNA-binding proteins. In
addition, the RNP-CS motifs of the TET family members contain an
unusually long predicted loop immediately after the first
helix
(3, 6, 23). The common structural features which are limited
to the TET family members suggest that they bind RNA and/or ssDNA in a
unique way. Moreover, Cabeza was found to be associated with the
majority of active transcription units in preparations of polythene
chromosomes from salivary gland nuclei (14), further
indicating that the TET family members participate in a function common
to the expression of most genes transcribed by Pol II.
The transformation of Ewing cells by EWS-FLI-1 is dependent on the
activity of both the EWS N-terminal domain and the FLI-1 DBD (18,
39). To assess the contribution of the N-terminal domain of the
EWS protein to the formation of human solid tumors, it is important to
understand the normal function(s) of EWS. The structural homology
between EWS and the transcription factor hTAFII68 (70%
similarity among the full-length proteins) strongly suggested that
there may be a functional homology between these proteins. Thus, we
investigated whether EWS and the EWS-FLI-1 fusion protein are able to
interact with the same multiprotein complexes as hTAFII68. We demonstrate that EWS, like hTAFII68, is able to
associate with a portion of the basal transcription factor TFIID. Using
an in vitro protein-protein interaction assay, we show that both EWS and hTAFII68 interact with several subunits
(TAFIIs) of the TFIID complex. EWS, similarly to
hTAFII68, copurifies with the endogenous Pol II. Moreover,
the subunits of the Pol II complex that interact directly with either
EWS or hTAFII68 were identified, further confirming the
importance of EWS and hTAFII68 in Pol II transcription. Using Ewing cell nuclear extracts (NEs), we studied the association of
EWS and the oncogenic fusion protein, EWS-FLI-1, with different multiprotein complexes. These experiments suggest that EWS and EWS-FLI-1 behave differently since EWS-FLI-1 cannot stably associate with any of the targets of EWS identified to date.
 |
MATERIALS AND METHODS |
Cell lines and NEs.
Two Ewing cell lines expressing
different EWS-FLI-1 chimeric transcripts were used: COH (ICB104),
which expresses a fusion transcript linking exon 10 of EWS to exon 6 of
FLI-1 (EWS 10/FLI 6); and RD-ES, which expresses a type II fusion
transcript linking exon 7 of EWS to exon 5 of FLI-1 (EWS 7/FLI 5)
(12). NEs were prepared as previously described
(5).
Immunization and antibody production.
To generate the
anti-EWS polyclonal antibody (PAb) 677, a peptide corresponding to
amino acids 136 to 152 of the EWS protein was synthesized, coupled to
keyhole limpet hemacyanin carrier protein (Neosystem Laboratories), and
used for immunization of rabbits. MAbs raised against
hTAFII68 (2B10), hTAFII100 (2D2), hTBP (3G3 and
2C1), the C-terminal domain (CTD) of the largest subunit of Pol II
(7G5), and FLI-1 (7.3) have been described previously (3-5, 9,
15, 21).
Immunoprecipitation and Western blot analysis.
Routinely,
100 to 500 µl (approximately 500 µg) of the indicated protein
fractions was immunoprecipitated with 50 µl of protein G-Sepharose
(Pharmacia) and approximately 2 µg of the different antibodies (as
indicated in the figure legends). Antibody-protein G-Sepharose-bound
protein complexes were washed three times with immunoprecipitation
buffer (25 mM Tris-HCl [pH 7.9], 10% [vol/vol] glycerol, 0.1%
Nonidet P-40, 0.5 mM dithiothreitol, 5 mM MgCl2) containing
0.5 M KCl and two times with immunoprecipitation buffer containing 100 mM KCl. After washing, 20 µl of the beads was boiled in sodium
dodecyl sulfate (SDS) sample buffer, and protein was analyzed by
SDS-polyacrylamide gel electrophoresis (PAGE). Protein samples were
then transferred to a nitrocellulose membrane and probed with the
indicated primary antibodies. As secondary antibodies, either
peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG)-IgM (heavy
plus light chain)-specific (Jackson ImmunoResearch Laboratories, Inc.)
or peroxidase-conjugated goat anti-mouse
-type light-chain-specific
(Southern Biotechnology Associates, Inc.) antibody was used. Detection
with an enhanced chemiluminescence kit (Amersham) was performed by
standard methods.
Construction of baculovirus expression vectors for EWS,
hTAFIIs, and subunits of Pol II and protein
expression.
The EWS cDNA (STA ET 19 [29]) was
excised from the Bluescript vector (pBSK+) by
EcoRI/DraI digestion and inserted in the EcoRI/SmaI sites of the pVL1392 vector. The
hTAFII68 cDNA was excised from the pBSK+ vector by
BamHI/XbaI digestion and inserted in the
corresponding sites of the pVL1393 vector. The other constructions encoding the different hTAFIIs or hTBP have been described
previously (9). Constructions of baculovirus expression
vectors for the human Pol II subunits have previously been described
(1). SF9 cell infection, plaque purification, and whole-cell
extract (WCE) preparation were performed as previously described
(1, 26).
Expression and purification of GST fusion proteins.
The
cDNAs encoding the glutathione S-transferase
(GST)-hTAFII68 or GST-EWS deletion mutants were amplified
by PCR using the appropriate oligonucleotides with either
BamHI/XhoI or EcoRI/XhoI sites. The PCR products were digested with the appropriate restriction enzymes and inserted in frame into the corresponding sites of the
pGEX-4-T3 vector (Pharmacia). All constructions were sequenced. GST
fusion protein overexpression and purification were performed as
previously described (32).
Protein-protein interaction assay.
GST fusion proteins (1 to
2 µg) attached to 20 µl of glutathione-agarose (Pharmacia) were
incubated with 200 to 500 µl of SF9 protein extracts containing the
various TAFIIs or Pol II subunits in buffer G (25 mM
Tris-HCl [pH 7.3], 10% [vol/vol] glycerol, 1% Triton X-100, 1 mM
dithiothreitol, 5 mM MgCl2) containing 0.5 M NaCl for
2 h at room temperature. The beads were washed three times with 1 ml of buffer G containing 1 M NaCl and once with buffer G containing
100 mM NaCl. Beads were boiled in SDS sample buffer, and protein was
analyzed by SDS-PAGE. The gel was either subjected to autoradiography
or transferred to a nitrocellulose filter and probed with the
appropriate antibodies.
Glycerol gradients.
HeLa and RD-ES cell NE (2 mg) and
high-molecular-weight markers (Pharmacia) were separately centrifuged
through a 20 to 40% glycerol gradient as described previously
(10, 11). Each 4-ml gradient was then fractionated into 30 140-µl fractions; 25 µl from each fraction was analyzed by Western
blotting using antibodies raised against the CTD of the largest subunit
of Pol II (MAb 7G5), hTAFII100 (MAb 2D2), TBP (MAb 3G3),
EWS (PAb 677), hTAFII68 (MAb 2B10), EWS (PAb 677), and
EWS-FLI-1 (MAb 7.3). The glycerol gradient concentration in each
fraction was determined to ensure that the gradients were linear. The
Western blots were quantified with a Bio-Rad densitometer.
 |
RESULTS |
Similarly to TAFII68, EWS interacts with TFIID and
copurifies with Pol II.
As two members of the TET family have
previously been shown to be substoichiometric components of distinct
TFIID complexes, we examined whether a third member of the TET family,
EWS, can also associate with TFIID. TFIID complexes were immunopurified from HeLa cell NEs by using either an anti-TBP or an
anti-TAFII100 MAb, and the presence of EWS in these
complexes was verified by Western blot analysis using an anti-EWS PAb
(Fig. 1A). While the anti-TBP and the
anti-TAFII100 immunoprecipitations depleted all TBP and
hTAFII100 from the NE (data not shown), about 10% of the input EWS was specifically retained in both the anti-TBP and the anti-TAFII100 immunoprecipitations but not in the control
immunoprecipitation (carried out with an unrelated anti-GAL4 MAb; lane
1). Similar results were obtained when the immunoprecipitations were
carried out in the presence of RNase (data not shown). These data
indicate that a fraction of EWS can associate with TFIID. To further
confirm the EWS-TFIID interaction and to analyze putative
EWS-associated proteins, the anti-EWS PAb was tested for its ability to
immunoprecipitate the nondenatured EWS protein. As shown in Fig. 1B,
lane 2, the anti-EWS PAb recognized native EWS protein, since it
immunoprecipitated EWS from the NE. Next we analyzed whether components
of the TFIID complex would coimmunoprecipitate with EWS. Consistent
with the anti-TBP and anti-TAFII100 immunoprecipitations,
the anti-EWS PAb specifically coimmunoprecipitated about 5 to 10% of
the input TBP and 15% of the input hTAFII100 (Fig. 1C,
lane 2; see Materials and Methods). Analysis of either the EWS- or the
hTAFII100-bound proteins by silver staining indicated that
the association of EWS with TFIID is substoichiometric (data not
shown). Together, these data demonstrate that, similarly to its
structural homologs hTAFII68 and TLS/FUS, EWS can be found
associated with a TFIID subpopulation in HeLa cell NEs.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
EWS is associated with TFIID and copurifies with Pol II.
(A) The anti-hTBP ( -TBP) and the anti-hTAFII100
( -TAFII100) MAbs coimmunoprecipitate EWS from a HeLa
cell NE. HeLa cell NE was immunoprecipitated (IP) with either an
unrelated antibody (lane 1) or a MAb raised against TBP (3G3; lane 2)
or hTAFII100 (2D2; lane 3). Beads were washed and boiled,
and bound proteins were analyzed by Western blotting using an antibody
raised against the N-terminal domain of EWS that recognizes the
endogenous EWS protein in HeLa cell NE (lane 4). M, markers in
kilodaltons. (B and C) The anti-EWS antibody coimmunoprecipitates
components of the TFIID complex. HeLa cell NE was immunoprecipitated
with either the anti-EWS PAb (lanes 2) or the preimmune serum (PI;
lanes 1). Beads were washed and boiled, and bound proteins were
analyzed by Western blotting using either the anti-EWS antibody (B) or
the anti-TBP MAb 3G3 together with the anti-hTAFII100 MAb
2D2 (C). In panel B, the IgG heavy chain (IgGH) is indicated. (D) EWS
copurifies with Pol II. The previously described chromatographic
fractions obtained during the purification of Pol II (3)
were tested by Western blotting using an antibody raised against either
EWS (upper panel) or the fifth-largest subunit of Pol II (hRPB5; lower
panel). Hep, Heparin-Ultrogel column; DE, DEAE 5PW HPLC column; ,
Phenyl-5PW HPLC column.
|
|
We have shown previously that only a fraction of the total cellular
hTAFII68 is associated with TFIID and that
hTAFII68 can also be found associated with Pol II
(3). Thus, we analyzed whether EWS could copurify with Pol
II and tested the fractions from our Pol II purification for the
presence of EWS. As shown in Fig. 1D, EWS copurifies with Pol II over
five chromatography columns, as determined by Western blotting using
antibodies raised against EWS and the 25-kDa subunit of Pol II (hRPB5)
(Fig. 1D) (3). The highly purified Pol II (lane 4) is free
of other basal Pol II transcription factors and is active in
transcription initiation and elongation (9). This result
suggests that, like hTAFII68, EWS is tightly associated
with Pol II (see also below).
Interaction of EWS and hTAFII68 with individual
components of the TFIID complex.
To identify the subunits of TFIID
that interact directly with either EWS or hTAFII68, the
TAFIIs and EWS or the TAFIIs and hTAFII68 were tested pairwise in a protein-protein
interaction assay. To this end, cDNAs encoding most of the human
TAFIIs and hTBP were inserted in baculovirus expression
vectors (9), and each TFIID subunit was expressed either
alone or together with EWS or hTAFII68 in SF9 cells. WCEs
were made, and protein expression was tested (Fig.
2A and C). From these extracts, either
EWS or hTAFII68 was immunoprecipitated, and bound proteins
were analyzed by Western blotting (Fig. 2B and D; Table
1). Extracts in which EWS or
hTAFII68 were either not expressed (Fig. 2B and D, lanes 1 and 3) or expressed alone (data not shown) served as negative controls
for the immunoprecipitations. Since the overexpressed proteins in SF9
cell extracts greatly exceed (by at least 1,000-fold) the endogenous
insect cell TAFII or EWS concentrations, these interaction
studies indicate that both EWS and hTAFII68 bind directly to hTAFII100 (Fig. 2B and D, lanes 4), hTAFII55
(lanes 2), hTAFII28, and hTAFII18 (Table 1).
The fact that EWS and hTAFII68 contact the same
TAFIIs in this direct protein-protein interaction assay and
that the anti-EWS PAb does not coimmunoprecipitate hTAFII68 from crude HeLa cell NE (data not shown) suggests that the presence of
EWS and that of hTAFII68 in the same TFIID complex are
mutually exclusive.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Interactions of EWS and hTAFII68 with other
components of the human TFIID complex. SF9 cells were coinfected with
recombinant baculoviruses expressing hTAFII100 and
hTAFII55 either individually or pairwise with EWS (A) and
hTAFII68 (C) as indicated. After 44 h of infection,
proteins were radiolabeled with [ -35S]methionine and
[ -35S]cysteine for 4 h. WCEs were made, proteins
were separated by SDS-PAGE, and gels were dried and subjected to
autoradiography. M, markers in kilodaltons. (B and D) From the protein
extracts, EWS and TAFII68 were immunoprecipitated (IP) with
either the anti-EWS ( -EWS) PAb (B) or the anti-hTAFII68
( -TAFII68) MAb (D) as indicated. Resin-bound proteins
were analyzed by Western blotting with antibodies raised against either
EWS, hTAFII100, and hTAFII55 separately (B) or
hTAFII68, hTAFII100, and hTAFII55
(D). In panel B, peroxidase-conjugated goat anti-mouse IgG-IgM-specific
secondary antibodies were used; in panel D, peroxidase-conjugated goat
anti-mouse -type light-chain-specific secondary antibody was used.
IgGH, IgG heavy chain.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Comparison of the interactions of EWS and
hTAFII68 with individual components of the TFIID complex in
baculovirus-coinfected SF9 cells
|
|
Interaction of EWS and hTAFII68 with subunits of the
RNA polymerase II.
To confirm the tight association of EWS or
hTAFII68 with Pol II, pairwise interactions of EWS or
hTAFII68 with individual subunits of the Pol II complex
were tested. cDNAs encoding almost all the human Pol II subunits were
inserted in baculovirus expression vectors (1), and each
subunit was expressed either alone or together with EWS or
hTAFII68 in SF9 cells. Proteins were radiolabeled with
[
-35S]methionine and [
-35S]cysteine,
WCEs were made, and the protein expression was examined by
autoradiography (Fig. 3A and C). From
these extracts, either EWS or hTAFII68 was
immunoprecipitated by using the appropriate antibodies, and EWS- or
hTAFII68-bound proteins were analyzed (Fig. 3B and D and
data not shown). Extracts in which EWS or hTAFII68 were not
expressed served as negative controls for the immunoprecipitations. These interaction studies indicate that both EWS and
hTAFII68 bind directly to hRPB3, a specific subunit of Pol
II (Fig. 3B and Table 2). Moreover,
hTAFII68 also interacts with two other Pol II subunits,
hRPB5 and hRPB7 (Fig. 3D and Table 2). These results suggest that EWS
and hTAFII68 may directly contact these Pol II subunits in
the endogenous Pol II complex (see also Discussion).

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 3.
Interactions between EWS or hTAFII68 and the
different subunits of Pol II. (A and C) SF9 cells were coinfected with
recombinant baculoviruses expressing subunits of Pol II either
individually or pairwise with EWS and hTAFII68 as
indicated. After 44 h of infection, proteins were radiolabeled
with [ -35S]methionine and
[ -35S]cysteine for 4 h. WCEs were made, proteins
were separated by SDS-PAGE, and gels were dried and subjected to
autoradiography. M, markers in kilodaltons. (B and D) From the WCEs,
EWS or hTAFII68 was immunoprecipitated (IP) with either the
anti-EWS ( -EWS) antibody or the anti-hTAFII68
( -TAFII68) MAb as indicated. Resin-bound proteins were
then analyzed by SDS-PAGE followed by autoradiography. The asterisk
indicates a nonspecific protein species.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparison of the interactions of EWS and
hTAFII68 with individual subunits of the Pol II in
baculovirus-coinfected SF9 cells
|
|
Mapping the domains of EWS and hTAFII68 which interact
with the subunits of TFIID and Pol II.
Since the N-terminal
domains of EWS and TLS/FUS play a specific role in tumorigenic
processes (7, 8), it is important to characterize the
interactions in which the N-terminal region of the TET proteins are
involved. To this end, we generated GST fusion proteins which contain
either the N-terminal (GST-EWSNt) or C-terminal (GST-EWS
Nt) halves
of EWS and hTAFII68 (Fig. 4). Note that the GST-EWSNt fusion protein contains the N-terminal domain
present in the type II EWS-FLI-1 oncogenic fusion protein. The GST
fusion proteins (or GST alone) were expressed in Escherichia coli, bound on glutathione-agarose beads, and incubated with SF9 cell protein extracts in which the different human TAFIIs
or Pol II subunits were overexpressed (see above and Fig. 4). The beads were then extensively washed, and bound proteins were analyzed by
either Western blotting or autoradiography (Fig. 4). The immobilized N-terminal domain of either TAFII68 or EWS retained
specifically TAFII100, while TAFII18 bound more
specifically to the CTDs of hTAFII68 and EWS (Fig. 4). The
binding of TAFII55 and TAFII28 to the truncated
hTAFII68 or EWS fusion proteins was less specific, suggesting that they may interact with several regions of
TAFII68 or EWS. These results indicate that the N-terminal
regions of EWS and hTAFII68 clearly retain the interaction
with hTAFII100 but do not retain, or retain only weakly,
interactions with the other TAFIIs that were shown to
interact with the full-length proteins.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Mapping the domains of EWS and hTAFII68
which interact with the subunits of TFIID and Pol II. Numbers in the
diagrams refer to amino acid positions in either hTAFII68
or EWS. The results of the protein-protein interaction assay, using
either baculovirus-overexpressed full-length proteins or E. coli-produced GST fusion proteins, are summarized as follows: +++,
++, +, +/ , and , strong, moderate, weak, very weak but detectable,
and no interactions between the indicated proteins.
|
|
Interestingly, all of the polymerase subunits which interacted with the
full-length hTAF
II68 bound specifically to the N-terminal
region of TAF
II68 (Fig.
4), indicating that the N-terminal
region
of hTAF
II68 plays an important role in the tight
association between
the Pol II complex and hTAF
II68. In
contrast, the binding of the
polymerase subunits to the different EWS
fusion proteins was unexpected.
The hRPB3 subunit, which bound to the
full-length EWS, did not
interact with the isolated regions of EWS, and
hRPB5 and hRPB7,
which did not interact with the full-length EWS,
interacted with
both halves of EWS (Fig.
4). These results, together
with the
observation that the full-length EWS is able to interact with
its separated CTD (data not shown), suggest that either an
intramolecular
interaction(s) takes place within the full-length EWS or
EWS is
able to multimerize. Thus, it appears that the distinct domains
of EWS are differently accessible in the full-length protein than
they
are in the separated GST fusion proteins. This finding further
suggests
that the full-length EWS and EWS-FLI-1 may interact differently
with
TFIID and Pol II.
EWS, but not EWS-FLI-1, interacts with TFIID and Pol II.
The
fact that the N-terminal domain of EWS retained its ability to interact
with TAFII100 prompted us to examine whether the oncogenic
fusion protein EWS-FLI-1 is also associated with TFIID. To answer this
question, we analyzed the TFIID composition from two Ewing sarcoma cell
lines (RD-ES and COH); These cell lines express different fusion
transcripts between EWS and FLI-1 which give rise to a 520-amino-acid
fusion protein in the case of the RD-ES cells and a 582-amino-acid
fusion protein in the case of the COH cells. NEs were made from these
cell lines expressing the two different EWS-FLI-1 fusion proteins.
Expression of the fusion oncoproteins was compared to that of the germ
line EWS by Western blot analysis using the anti-EWS PAb (Fig.
5A, upper panel) and the anti-FLI-1
antibody (Fig. 4A, middle panel). The anti-EWS PAb was raised against a
common region present in the N-terminal domains of both the EWS and
EWS-FLI-1 fusion proteins, and the anti-FLI-1 antibody was raised
against the C-terminal end of FLI-1 (21). In the NEs of the
Ewing sarcoma cells, the anti-EWS antibody recognized both EWS and the
EWS-FLI-1 proteins (Fig. 5A, upper panel, lanes 2 and 3). Moreover, it
appears that both Ewing sarcoma cell lines tested express about three
times less EWS-FLI-1 protein than germ line EWS. The same two
EWS-FLI-1 fusion oncoproteins were also recognized by the anti-FLI-1
MAb in the NE of the Ewing sarcoma cell lines (Fig. 5A, middle panel, lanes 2 and 3); however, this antibody did not recognize any protein in
the HeLa NE (lane 1). Next, we prepared TBP-containing complexes from
the Ewing sarcoma cell and the HeLa NEs by an anti-TBP
immunoprecipitation and tested the presence of EWS or EWS-FLI-1 in the
immunoprecipitated TBP-containing complexes by Western blot analysis
(Fig. 5B). Similar to the TFIID-EWS coimmunoprecipitation from HeLa
cell NE (Fig. 1A and 5B, lane 1), EWS coimmunoprecipitated with TBP
from the two Ewing sarcoma cell NEs (Fig. 5B, lanes 2 and 3). Moreover, the anti-TAFII100 MAb coimmunoprecipitated EWS from the
RD-ES cell line (data not shown). In contrast, no EWS-FLI-1 was
detected in the immunoprecipitated TFIID complexes by Western blot
analysis using the anti-EWS PAb (lanes 2 and 3), even after very long
exposures of the Western blots. Moreover, no EWS-FLI-1 fusion proteins
were observed to be associated with the TBP-containing complexes when the antibody raised against the C terminus of FLI-1 was used (reference 21 and data not shown). This finding suggests that
the oncogenic EWS-FLI-1 fusion proteins do not associate with TFIID in
the two Ewing sarcoma cell lines tested.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
The oncogenic fusion protein EWS-FLI-1 does not
coimmunoprecipitate with the TFIID complex in Ewing sarcoma cell lines.
(A) The PAb raised against the N-terminal domain of EWS recognizes both
wild-type EWS and the two different EWS-FLI-1 fusion proteins in NEs
from the two Ewing sarcoma cell lines, RD-ES (lane 2) and COH (lane 3).
NEs from HeLa, RD-ES and COH cells were analyzed by Western blotting
using the anti-EWS ( -EWS) antibody (upper panel), the anti-FLI-1
( -FLI-1) MAb (middle panel), and the anti-TBP ( -TBP) MAb 3G3
(lower panel). M, markers in kilodaltons. (B) NEs from the various cell
lines were immunoprecipitated (IP) with the anti-TBP MAb 3G3 (lane 1 to
3). Beads were washed and boiled, and bound proteins were analyzed by
Western blotting with the anti-EWS antibody and the anti-TBP MAb. The
control immunoprecipitation using an unrelated MAb is shown in lane
4.
|
|
Using several different in vitro approaches, we have shown that
portions of EWS and hTAF
II68 are associated with either
TFIID
or Pol II. To further investigate the association of EWS and
hTAF
II68
with these multiprotein complexes under more
physiological conditions,
we determined the native molecular masses of
hTAF
II68 and EWS
from the HeLa and RD-ES cell lines as well
as the apparent native
molecular mass of the oncogenic fusion protein
EWS-FLI-1 from
the RD-ES cell line. Human HeLa and RD-ES NEs were made
and centrifuged
through a 20 to 40% glycerol gradient, and no further
manipulations
were performed on the crude extracts to ensure that
high-molecular-weight
complexes remained intact. The sedimentation of
hTAF
II68, EWS,
and EWS-FLI-1 was compared with that of
components of TFIID (TBP
and TAF
II100) and Pol II (the
largest subunit of the Pol II complex)
multiprotein complexes, as well
as markers of known molecular
mass. With the exception of EWS-FLI-1,
similar results were obtained
in analyses of fractions from either HeLa
or RD-ES NEs (Fig.
6 and data not shown).
Most of hTAF
II68 and about 40% of EWS cosedimented
in
fractions corresponding to high molecular masses (between 400
and 1,300 kDa [Fig.
6C, fractions 10 to 20]) that contained TFIID
and a portion
of Pol II (Fig.
6A and B). This cosedimentation
further suggests that
the previously found association of EWS
and hTAF
II68 with
the TFIID and Pol II complexes may be physiologically
relevant. In
contrast, the majority of EWS-FLI-1 was detected
by Western blot
analysis using an anti-FLI-1 antibody in the low-molecular-mass-range
fractions (between 67 and 160 kDa [Fig.
5D, fractions 2 to 9]).
As
both the TFIID and the Pol II complexes have native molecular
masses
greater than 600 kDa, this result, together with the
immunoprecipitation
data (see above), suggests that in contrast to EWS,
EWS-FLI-1
is not stably associated with TFIID or Pol II.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
Sedimentation of RD-ES cell NE through a 20 to 40%
glycerol gradient indicates that the endogenous EWS-FLI-1 fusion
protein is present in low-molecular-mass ranges. The relative
sedimentations of the largest subunit of Pol II (A),
TAFII100 and TBP (B), EWS and TAFII68 together
(C), and EWS-FLI-1 (D) were determined by Western blotting using
antibodies raised against either the CTD of the largest subunit of Pol
II (A), TAFII100 and TBP (B), or EWS and
TAFII68 (C). To better visualize EWS-FLI-1 that is only
weakly detected in panel C by the EWS antibody, in panel D the
anti-FLI-1 antibody was used. In each panel, the upper part shows a
quantification of the Western blot. Values represent the percentage of
a given protein present in each fraction compared to the total amount
of this protein loaded on the glycerol gradient. Positions of markers
(M) of known molecular mass standards are indicated at the top of panel
A.
|
|
 |
DISCUSSION |
Possible functions of the TET proteins in transcription initiation
and elongation.
Previously, two members of the TET family
(hTAFII68 and TLS/FUS) were shown to interact with
functionally different TFIID complexes (3). In this study,
we show that the third human member of the TET family (EWS) can also
associate with endogenous TFIID. These findings indicate that the TET
family members have not only structural but also functional homology.
hTAFII68 and TLS/FUS were described as specific
TAFIIs since they were found to be associated with
functionally distinct TFIID subpopulations (3, 5).
Similarly, the association of EWS with TFIID is substoichiometric,
suggesting that it associates only with a subpopulation of TFIID and
thus EWS can also be considered a specific TAFII. The high
homology among EWS, TLS/FUS, and hTAFII68 and common properties to associate with complexes involved in Pol II transcription suggest that they may play a common role in transcription initiation and/or elongation.
The fact that hTAF
II68 and EWS interact with the same core
TAF
IIs and that hTAF
II68 and TLS/FUS are not
present in the same
TFIID subpopulations strongly suggests that these
proteins cannot
both be present in the same TFIID complexes. In
agreement with
this conclusion, we could not coimmunoprecipitate EWS
(or TLS/FUS)
with hTAF
II68 or vice versa. Moreover, the
presence of one of
these RNA- and/or ssDNA-binding proteins in a
distinct TFIID complex
may distinguish a particular TFIID complex, at
least partly, from
the other different TFIID complexes. Thus, the
different TET proteins-containing
TFIID complexes may have a specific
role in the preinitiation
complexes and/or may define the promoter
selectivity of the distinct
TFIID complexes.
Only a fraction of the total cellular amount of EWS binds to TFIID.
Another fraction of endogenous EWS copurifies with the
Pol II complex
on five subsequent chromatographic columns, similarly
to
hTAF
II68, suggesting an association between EWS and the Pol
II complex. The association of EWS or hTAF
II68 with Pol II
was
confirmed by mapping possible contact points between these two
TET
proteins and subunits of Pol II. This mapping indicated that
while both
EWS and hTAF
II68 interacted with the third-largest
subunit
of the human Pol II (hRPB3), only hTAF
II68 interacted
with
hRPB5 and hRPB7. Thus, despite the fact that the members
of the TET
family are functional homologs, they may differ in
the capacity to
interact with other proteins.
Involvement of the N-terminal domains of EWS and
hTAFII68 in the interactions with TFIID and Pol II.
To
understand more about the mechanisms by which the chimeric
sarcoma-associated oncogenes induce tumor formation, it is important to
study the involvement of their N-terminal domains in the
above-described interactions (see also the introduction).
TAFII100 was the only TFIID subunit that bound reasonably
well to the N-terminal domain of EWS or hTAFII68. This
finding suggests that the interactions between the endogenous TFIID
complex and EWS-FLI-1 are considerably weaker than those between EWS
and TFIID (see also below). Since the baculovirus-overexpressed
EWS-FLI-1 is very insoluble, we could not investigate the interactions
between the different TAFIIs and EWS-FLI-1. The other
TAFII interactions with EWS and hTAFII68 either
mapped in the CTDs of EWS and hTAFII68 or could not be clearly determined with the GST fusion proteins used. The interactions mapped between the CTD of EWS and the different TAFIIs
suggest that this domain plays an important role in the stable
association of full-length EWS with TFIID. These results suggest that
the complex network of interactions occurring between EWS and the TFIID
complex may be seriously impaired in the case of the EWS-FLI-1 oncogenic fusion protein that contains only the N-terminal domain of
EWS (see also below).
The N-terminal domain of hTAF
II68 retained the ability to
interact with all of the Pol II subunits which were found to interact
with the full-length protein, indicating that this domain of
hTAF
II68
plays an important role in the tight association
between hTAF
II68
and the Pol II complex. Unexpectedly, none
of the isolated domains
of EWS interact with the Pol II subunit which
interacts with the
full-length EWS. This finding suggests that within
the EWS protein,
an intramolecular interaction(s) occurs and that a
particular
conformation of EWS is involved in the interaction(s) with
Pol
II. Consistent with this hypothesis, an in vitro interaction
between
the full-length EWS and its C-terminal region can be detected
(data not shown). Based on these observations, we propose a model
where
EWS may exist in the cells in a conformation in which the
N-terminal
domain of the protein is not accessible. This form
of EWS may then bind
to Pol II through hRPB3. However, following
interaction with a certain
cellular target(s) or after a posttranslational
modification(s), EWS
may change its conformation such that its
N-terminal domain becomes
accessible. This modified form of EWS
would be able to interact with
other Pol II subunits, hRPB5 and
hRPB7. The interaction between the
N-terminal domain of EWS and
hRPB7 has also been identified
independently in a yeast two-hybrid
screen using the first 82 amino
acids of EWS as a bait (
28).
Importantly, this short
82-amino-acid region of EWS has been previously
shown to be sufficient
for nearly full transforming activity of
EWS (
18). Thus,
this interaction between the transcriptional
activator EWS-FLI-1 and
the Pol II complex, which may not occur
between wild-type FLI-1 and Pol
II, seems to play an important
role in the deregulation of gene
expression in the sarcoma cells.
EWS-FLI-1 cannot stably associate with Pol II and TFIID but may
interact with these complexes as a transcriptional activator.
The
aberrant transcription factor EWS-FLI-1 transforms the cells by either
interfering in the function of germ line EWS, having a
dominant-negative effect on the function of EWS, or modifying the
FLI-1-regulated gene expression. The fact that EWS-FLI-1 does not
coimmunoprecipitate with TFIID from RD-ES and COH cells (Fig. 5B) and
that in the RD-ES cell NEs EWS-FLI-1 can be found predominantly in
low-molecular-weight ranges indicates that EWS-FLI-1 is not stably
associated with any multiprotein complexes in these cells. This
suggests that the interactions mapped between the C-terminal half of
EWS and the TFIID subunits are critical for the stable association of
full-length EWS with the TFIID complex. Moreover, there is also a
dramatic change in the Pol II subunits which interact either with the
full-length EWS or with its N-terminal domain (Fig. 4). Thus, it is
unlikely that EWS-FLI-1 can have a dominant-negative effect on the
function of the portion of EWS which is associated with the TFIID
and/or Pol II multiprotein complexes. Note that another portion of EWS
may be involved in functions that are yet unknown. EWS-FLI-1 has been
shown to function as a transcriptional activator on different
FLI-1-binding sites containing test promoters (2). Our
finding that EWS-FLI-1 is not associated with any multiprotein
complexes is in agreement with this finding since to date none of the
known transcriptional activators have been found tightly associated
with TFIID or Pol II. However, transcriptional activators are known to
interact with components of the basal transcription machinery, e.g.,
TAFIIs, TBP, and Pol II, to enhance transcription of the
different target genes (36, 38). The efficiency and the
stability of the interactions between the N-terminal domain of EWS and
TFIID or Pol II may also be very different from those in which
wild-type FLI-1 participates. These differences seems to be important
for the transformation capability of EWS-FLI-1.
 |
ACKNOWLEDGMENTS |
We thank H. Kovar and R. Petermann for discussing unpublished
results, I. Kolb-Cheynel for expression of hTAFIIs, Pol II
subunits, and EWS in the baculovirus system; J. Ghysdael, V. Dubrovskaya, X. Jacq, A. C. Lavigne, G. Mengus, and I. Davidson
for different reagents; F. J. Dilworth and C. Kedinger for
critical reading of the manuscript; Y. Lutz for antibody preparations;
the cell culture group for cells; and C. Werlé and J.-M.
Lafontaine for illustrations and photography.
A.B. was supported by a fellowship from Association pour la Recherche
contre le Cancer. This work was supported by grants from the CNRS,
INSERM, Centre Hospitalier Universitaire Régional, Ministère de la Recherche et Technologie, and Fondation pour la
Recherche Médicale to L.T. and the Association pour la Recherche contre le Cancer to C. Kedinger and L.T.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut de
Génétique et de Biologie Moléculaire et Cellulaire,
CNRS/INSERM/ULP, BP 163, F-67404 ILLKIRCH Cedex, C.U. de Strasbourg,
France. Phone: (33) 3 88 65 34 44. Fax: (33) 3 88 65 32 01. E-mail:
laszlo{at}titus.u-strasbg.fr.
 |
REFERENCES |
| 1.
|
Acker, J.,
M. de Graaff,
I. Cheynel,
V. Khazak,
C. Kedinger, and M. Vigneron.
1997.
Interactions between the human RNA polymerase II subunits.
J. Biol. Chem.
272:16815-16821[Abstract/Free Full Text].
|
| 2.
|
Bailly, R. A.,
R. Bosselut,
J. Zucman,
F. Cormier,
O. Delattre,
M. Roussel,
G. Thomas, and J. Ghysdael.
1994.
DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.
Mol. Cell. Biol.
14:3230-3241[Abstract/Free Full Text].
|
| 3.
|
Bertolotti, A.,
Y. Lutz,
D. J. Heard,
P. Chambon, and L. Tora.
1996.
hTAFII68 a novel RNA/SSDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II.
EMBO J.
15:5022-5031[Medline].
|
| 4.
|
Besse, S.,
M. Vigneron,
E. Pichard, and F. Puvlon-Dutilleul.
1995.
Synthesis and maturation of viral transcripts in herpes simplex virus type 1 infected HeLa cells: the role of interchromatin granules.
Gene Expr.
4:143-161[Medline].
|
| 5.
|
Brou, C.,
S. Chaudhary,
I. Davidson,
Y. Lutz,
J. Wu,
J. M. Egly,
L. Tora, and P. Chambon.
1993.
Distinct TFIID complexes mediate the effect of different transcriptional activators.
EMBO J.
12:489-499[Medline].
|
| 6.
|
Burd, C. G., and G. Dreyfuss.
1994.
Conserved structures and diversity of functions of RNA-binding proteins.
Science
265:615-621[Abstract/Free Full Text].
|
| 7.
|
Crozat, A.,
P. Aman,
N. Mandahl, and D. Ron.
1993.
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma.
Nature
363:640-644[Medline].
|
| 8.
|
Delattre, O.,
J. Zucman,
B. Plougastel,
C. Desmaze,
T. Melot,
M. Peter,
H. Kovar,
I. Joubert,
P. de Jong,
G. Rouleau, et al.
1992.
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.
Nature
359:162-165[Medline].
|
| 9.
|
Dubrovskaya, V.,
A.-C. Lavigne,
I. Davidson,
J. Acker,
A. Staub, and L. Tora.
1996.
Distinct domains of hTAFII100 are required for functional interaction with transcription factor TFIIFb (RAP30) and incorporation into the TFIID complex.
EMBO J.
15:3702-3712[Medline].
|
| 10.
|
Fraser, R. A.,
M. Rossignol,
D. J. Heard,
J. M. Egly, and P. Chambon.
1997.
SUG1, a putative transcriptional mediator and subunit of the PA700 proteasome regulatory complex, is a DNA helicase.
J. Biol. Chem.
272:7122-7126[Abstract/Free Full Text].
|
| 11.
|
Gerard, M.,
L. Fischer,
V. Moncollin,
J. M. Chipoulet,
P. Chambon, and J. M. Egly.
1991.
Purification and interaction properties of the human RNA polymerase B(II) general transcription factor BTF2.
J. Biol. Chem.
266:20940-20945[Abstract/Free Full Text].
|
| 12.
|
Giovannini, M.,
J. A. Biegel,
M. Serra,
J. Y. Wang,
Y. H. Wei,
L. Nycum,
B. S. Emanuel, and G. A. Evans.
1994.
EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.
J. Clin. Invest.
94:489-496.
|
| 13.
|
Hurst, H. C.
1996.
Transcription factors as drug targets in cancer.
Eur. J. Cancer
32A:1857-1863.
|
| 14.
|
Immanuel, D.,
H. Zinszner, and D. Ron.
1995.
Association of SARFH (sarcoma-associated RNA-binding fly homolog) with regions of chromatin transcribed by RNA polymerase II.
Mol. Cell. Biol.
15:4562-4571[Abstract].
|
| 15.
|
Jacq, X.,
C. Brou,
Y. Lutz,
I. Davidson,
P. Chambon, and L. Tora.
1994.
Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor.
Cell
79:107-117[Medline].
|
| 16.
|
Labelle, Y.,
J. Zucman,
G. Stenman,
L. G. Kindblom,
J. Knight,
C. Turc-Carel,
B. Dockhorn-Dworniczak,
N. Mandahl,
C. Desmaze,
M. Peter, et al.
1995.
Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation.
Hum. Mol. Genet.
4:221-226.
|
| 17.
|
Ladanyi, M.
1995.
The emerging molecular genetics of sarcoma translocations.
Diagn. Mol. Pathol.
4:162-173[Medline].
|
| 18.
|
Lessnick, S. L.,
B. S. Braun,
C. T. Denny, and W. A. May.
1995.
Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.
Oncogene
10:423-431[Medline].
|
| 19.
|
Lewin, B.
1991.
Oncogenic conversion by regulatory changes in transcription factors.
Cell
64:303-312[Medline].
|
| 20.
|
May, W. A.,
M. L. Gishizky,
S. L. Lessnick,
L. B. Lunsford,
B. C. Lewis,
O. Delattre,
J. Zucman,
G. Thomas, and C. T. Denny.
1993.
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.
Proc. Natl. Acad. Sci. USA
90:5752-5756[Abstract/Free Full Text].
|
| 21.
|
Melot, T.,
N. Gruel,
A. Doubeikovski,
N. Sevenet,
J. L. Teillaud, and O. Delattre.
1997.
Production and characterization of mouse monoclonal antibodies to wild-type and oncogenic FLI-1 proteins.
Hybridoma
16:457-464[Medline].
|
| 22.
|
Meyers, S., and S. W. Hiebert.
1995.
Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1.
Crit. Rev. Eukaryotic Gene Expr.
5:365-383[Medline].
|
| 23.
|
Nagai, K.,
C. Oubridge,
T. H. Jessen,
J. Li, and P. R. Evans.
1990.
Crystal structure of the RNA-binding domain of the U1 small nuclear ribonucleoprotein A.
Nature
348:515-520[Medline].
|
| 24.
|
Ohno, T.,
M. Ouchida,
L. Lee,
Z. Gatalica,
V. N. Rao, and E. S. Reddy.
1994.
The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains.
Oncogene
9:3087-3097[Medline].
|
| 25.
|
Ohno, T.,
V. N. Rao, and E. S. Reddy.
1993.
EWS/Fli-1 chimeric protein is a transcriptional activator.
Cancer Res.
53:5859-5863[Abstract/Free Full Text].
|
| 26.
|
O'Reilly, D. R.,
L. K. Miller, and V. A. Luckow.
1992.
.
Baculovirus expression vectors. W. H.
Freeman, New York, N.Y.
|
| 27.
|
Peter, M.,
J. Couturler,
H. Pacquement,
J. Michon,
G. Thomas,
H. Magdelenat, and O. Delattre.
1997.
A new member of the ETS family fused to EWS in Ewing tumors.
Oncogene
14:1159-1164[Medline].
|
| 28.
| Petermann, R., B. M. Mossier, and H. Kovar.
Personal communication.
|
| 29.
|
Plougastel, B.,
J. Zucman,
M. Peter,
G. Thomas, and O. Delattre.
1993.
Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation.
Genomics
18:609-615[Medline].
|
| 30.
|
Rabbitts, T. H.,
A. Forster,
R. Larson, and P. Nathan.
1993.
Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
Nat. Genet.
4:175-180[Medline].
|
| 31.
|
Roeder, R. G.
1996.
Nuclear RNA polymerase: role of general initiation factors and cofactors in eukaryotic transcription.
Methods Enzymol.
273:165-171[Medline].
|
| 32.
|
Smith, D. B., and K. S. Johnson.
1988.
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.
Gene
67:31-40[Medline].
|
| 33.
|
Stolow, D. T., and S. R. Haynes.
1995.
Cabeza, a Drosophila gene encoding a novel RNA binding protein, shares homology with EWS and TLS, two genes involved in human sarcoma formation.
Nucleic Acids Res.
23:835-843[Abstract/Free Full Text].
|
| 34.
|
Turc-Carel, C.,
A. Aurias,
F. Mugneret,
S. Lizard,
I. Sidaner,
C. Volk,
J. P. Thiery,
S. Olschwang,
I. Phillp,
M. P. Berger, et al.
1988.
Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12).
Cancer Genet. Cytogenet.
32:229-238[Medline].
|
| 35.
|
Urano, F.,
A. Umezawa,
W. Hong,
H. Kikuchi, and J. Hata.
1996.
A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma.
Biochem. Biophys. Res. Commun.
2:608-612.
|
| 36.
|
Verrijzer, C. P., and R. Tjian.
1996.
TAFs mediate transcriptional activation and promoter selectivity.
Trends Biochem. Sci.
21:338-342[Medline].
|
| 37.
|
Wasylyk, B.,
S. L. Hahn, and A. Giovane.
1993.
The Ets family of transcription factors.
Eur. J. Biochem.
211:7-18[Medline].
|
| 38.
|
Yankulov, K.,
J. Blau,
T. Purton,
S. Roberts, and D. L. Bentley.
1994.
Transcriptional elongation by RNA polymerase II is stimulated by transactivators.
Cell
77:749-759[Medline].
|
| 39.
|
Zinszner, H.,
R. Albalat, and D. Ron.
1994.
A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
Genes Dev.
8:2513-2526[Abstract/Free Full Text].
|
Mol Cell Biol, March 1998, p. 1489-1497, Vol. 18, No. 3
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tan, A. Y., Manley, J. L.
(2009). The TET Family of Proteins: Functions and Roles in Disease. J Mol Cell Biol
1: 82-92
[Abstract]
[Full Text]
-
Suel, K. E., Chook, Y. M.
(2009). Kap104p Imports the PY-NLS-containing Transcription Factor Tfg2p into the Nucleus. J. Biol. Chem.
284: 15416-15424
[Abstract]
[Full Text]
-
Embree, L. J., Azuma, M., Hickstein, D. D.
(2009). Ewing Sarcoma Fusion Protein EWSR1/FLI1 Interacts with EWSR1 Leading to Mitotic Defects in Zebrafish Embryos and Human Cell Lines. Cancer Res.
69: 4363-4371
[Abstract]
[Full Text]
-
Torchia, E. C., Boyd, K., Rehg, J. E., Qu, C., Baker, S. J.
(2007). EWS/FLI-1 Induces Rapid Onset of Myeloid/Erythroid Leukemia in Mice. Mol. Cell. Biol.
27: 7918-7934
[Abstract]
[Full Text]
-
Ng, K. P., Potikyan, G., Savene, R. O. V., Denny, C. T., Uversky, V. N., Lee, K. A. W.
(2007). Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc. Natl. Acad. Sci. USA
104: 479-484
[Abstract]
[Full Text]
-
Anumanthan, G., Halder, S. K., Friedman, D. B., Datta, P. K.
(2006). Oncogenic Serine-Threonine Kinase Receptor-Associated Protein Modulates the Function of Ewing Sarcoma Protein through a Novel Mechanism.. Cancer Res.
66: 10824-10832
[Abstract]
[Full Text]
-
Aryee, D. N.T., Kreppel, M., Bachmaier, R., Uren, A., Muehlbacher, K., Wagner, S., Breiteneder, H., Ban, J., Toretsky, J. A., Kovar, H.
(2006). Single-chain Antibodies to the EWS NH2 Terminus Structurally Discriminate between Intact and Chimeric EWS in Ewing's Sarcoma and Interfere with the Transcriptional Activity of EWS In vivo.. Cancer Res.
66: 9862-9869
[Abstract]
[Full Text]
-
Toretsky, J. A., Erkizan, V., Levenson, A., Abaan, O. D., Parvin, J. D., Cripe, T. P., Rice, A. M., Lee, S. B., Uren, A.
(2006). Oncoprotein EWS-FLI1 Activity Is Enhanced by RNA Helicase A. Cancer Res.
66: 5574-5581
[Abstract]
[Full Text]
-
Law, W. J., Cann, K. L., Hicks, G. G.
(2006). TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief Funct Genomic Proteomic
5: 8-14
[Abstract]
[Full Text]
-
Robert, F., Hardy, S., Nagy, Z., Baldeyron, C., Murr, R., Dery, U., Masson, J.-Y., Papadopoulo, D., Herceg, Z., Tora, L.
(2006). The Transcriptional Histone Acetyltransferase Cofactor TRRAP Associates with the MRN Repair Complex and Plays a Role in DNA Double-Strand Break Repair. Mol. Cell. Biol.
26: 402-412
[Abstract]
[Full Text]
-
Perani, M., Antonson, P., Hamoudi, R., Ingram, C. J. E., Cooper, C. S., Garrett, M. D., Goodwin, G. H.
(2005). The Proto-oncoprotein SYT Interacts with SYT-interacting Protein/Co-activator Activator (SIP/CoAA), a Human Nuclear Receptor Co-activator with Similarity to EWS and TLS/FUS Family of Proteins. J. Biol. Chem.
280: 42863-42876
[Abstract]
[Full Text]
-
Meka, H., Werner, F., Cordell, S. C., Onesti, S., Brick, P.
(2005). Crystal structure and RNA binding of the Rpb4/Rpb7 subunits of human RNA polymerase II. Nucleic Acids Res
33: 6435-6444
[Abstract]
[Full Text]
-
Alex, D., Lee, K. A. W.
(2005). RGG-boxes of the EWS oncoprotein repress a range of transcriptional activation domains. Nucleic Acids Res
33: 1323-1331
[Abstract]
[Full Text]
-
Iko, Y., Kodama, T. S., Kasai, N., Oyama, T., Morita, E. H., Muto, T., Okumura, M., Fujii, R., Takumi, T., Tate, S.-i., Morikawa, K.
(2004). Domain Architectures and Characterization of an RNA-binding Protein, TLS. J. Biol. Chem.
279: 44834-44840
[Abstract]
[Full Text]
-
Townson, S. M., Kang, K., Lee, A. V., Oesterreich, S.
(2004). Structure-Function Analysis of the Estrogen Receptor {alpha} Corepressor Scaffold Attachment Factor-B1: IDENTIFICATION OF A POTENT TRANSCRIPTIONAL REPRESSION DOMAIN. J. Biol. Chem.
279: 26074-26081
[Abstract]
[Full Text]
-
Takahashi, A., Higashino, F., Aoyagi, M., Yoshida, K., Itoh, M., Kyo, S., Ohno, T., Taira, T., Ariga, H., Nakajima, K., Hatta, M., Kobayashi, M., Sano, H., Kohgo, T., Shindoh, M.
(2003). EWS/ETS Fusions Activate Telomerase in Ewing's Tumors. Cancer Res.
63: 8338-8344
[Abstract]
[Full Text]
-
Reynolds, P. A., Smolen, G. A., Palmer, R. E., Sgroi, D., Yajnik, V., Gerald, W. L., Haber, D. A.
(2003). Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev.
17: 2094-2107
[Abstract]
[Full Text]
-
Meka, H., Daoust, G., Arnvig, K. B., Werner, F., Brick, P., Onesti, S.
(2003). Structural and functional homology between the RNAPI subunits A14/A43 and the archaeal RNAP subunits E/F. Nucleic Acids Res
31: 4391-4400
[Abstract]
[Full Text]
-
Araya, N., Hirota, K., Shimamoto, Y., Miyagishi, M., Yoshida, E., Ishida, J., Kaneko, S., Kaneko, M., Nakajima, T., Fukamizu, A.
(2003). Cooperative Interaction of EWS with CREB-binding Protein Selectively Activates Hepatocyte Nuclear Factor 4-mediated Transcription. J. Biol. Chem.
278: 5427-5432
[Abstract]
[Full Text]
-
Laflamme, C., Filion, C., Bridge, J. A., Ladanyi, M., Goldring, M. B., Labelle, Y.
(2003). The Homeotic Protein Six3 Is a Coactivator of the Nuclear Receptor NOR-1 and a Corepressor of the Fusion Protein EWS/NOR-1 in Human Extraskeletal Myxoid Chondrosarcomas. Cancer Res.
63: 449-454
[Abstract]
[Full Text]
-
Spahn, L., Petermann, R., Siligan, C., Schmid, J. A., Aryee, D. N. T., Kovar, H.
(2002). Interaction of the EWS NH2 Terminus with BARD1 Links the Ewing's Sarcoma Gene to a Common Tumor Suppressor Pathway. Cancer Res.
62: 4583-4587
[Abstract]
[Full Text]
-
Kimura, M., Suzuki, H., Ishihama, A.
(2002). Formation of a Carboxy-Terminal Domain Phosphatase (Fcp1)/TFIIF/RNA Polymerase II (pol II) Complex in Schizosaccharomyces pombe Involves Direct Interaction between Fcp1 and the Rpb4 Subunit of pol II. Mol. Cell. Biol.
22: 1577-1588
[Abstract]
[Full Text]
-
Kovar, H., Jug, G., Hattinger, C., Spahn, L., Aryee, D. N. T., Ambros, P. F., Zoubek, A., Gadner, H.
(2001). The EWS Protein Is Dispensable for Ewing Tumor Growth. Cancer Res.
61: 5992-5997
[Abstract]
[Full Text]
-
Arvand, A., Welford, S. M., Teitell, M. A., Denny, C. T.
(2001). The COOH-Terminal Domain of FLI-1 Is Necessary for Full Tumorigenesis and Transcriptional Modulation by EWS/FLI-1. Cancer Res.
61: 5311-5317
[Abstract]
[Full Text]
-
Rossow, K. L., Janknecht, R.
(2001). The Ewing's Sarcoma Gene Product Functions as a Transcriptional Activator. Cancer Res.
61: 2690-2695
[Abstract]
[Full Text]
-
de Alava, E., Pardo, J.
(2001). Ewing Tumor: Tumor Biology and Clinical Applications. INT J SURG PATHOL
9: 7-17
[Abstract]
-
Yang, L., Embree, L. J., Hickstein, D. D.
(2000). TLS-ERG Leukemia Fusion Protein Inhibits RNA Splicing Mediated by Serine-Arginine Proteins. Mol. Cell. Biol.
20: 3345-3354
[Abstract]
[Full Text]
-
FANCIULLI, M., BRUNO, T., DI PADOVA, M., DE ANGELIS, R., IEZZI, S., IACOBINI, C., FLORIDI, A., PASSANANTI, C.
(2000). Identification of a novel partner of RNA polymerase II subunit 11, Che-1, which interacts with and affects the growth suppression function of Rb. FASEB J.
14: 904-912
[Abstract]
[Full Text]
-
Georgieva, S., Kirschner, D. B., Jagla, T., Nabirochkina, E., Hanke, S., Schenkel, H., de Lorenzo, C., Sinha, P., Jagla, K., Mechler, B., Tora, L.
(2000). Two Novel Drosophila TAFIIs Have Homology with Human TAFII30 and Are Differentially Regulated during Development. Mol. Cell. Biol.
20: 1639-1648
[Abstract]
[Full Text]
-
Bosilevac, J. M., Olsen, R. J., Bridge, J. A., Hinrichs, S. H.
(1999). Tumor Cell Viability in Clear Cell Sarcoma Requires DNA Binding Activity of the EWS/ATF1 Fusion Protein. J. Biol. Chem.
274: 34811-34818
[Abstract]
[Full Text]
-
Lin, P. P., Brody, R. I., Hamelin, A. C., Bradner, J. E., Healey, J. H., Ladanyi, M.
(1999). Differential Transactivation by Alternative EWS-FLI1 Fusion Proteins Correlates with Clinical Heterogeneity in Ewing's Sarcoma. Cancer Res.
59: 1428-1432
[Abstract]
[Full Text]
-
Miyao, T., Woychik, N. A.
(1998). RNA polymerase subunit RPB5 plays a role in transcriptional activation. Proc. Natl. Acad. Sci. USA
95: 15281-15286
[Abstract]
[Full Text]
-
Dorjsuren, D., Lin, Y., Wei, W., Yamashita, T., Nomura, T., Hayashi, N., Murakami, S.
(1998). RMP, a Novel RNA Polymerase II Subunit 5-Interacting Protein, Counteracts Transactivation by Hepatitis B Virus X Protein. Mol. Cell. Biol.
18: 7546-7555
[Abstract]
[Full Text]
-
Yang, L., Embree, L. J., Tsai, S., Hickstein, D. D.
(1998). Oncoprotein TLS Interacts with Serine-Arginine Proteins Involved in RNA Splicing. J. Biol. Chem.
273: 27761-27764
[Abstract]
[Full Text]
-
Zhang, D., Paley, A. J., Childs, G.
(1998). The Transcriptional Repressor ZFM1 Interacts with and Modulates the Ability of EWS to Activate Transcription. J. Biol. Chem.
273: 18086-18091
[Abstract]
[Full Text]
-
Knoop, L. L., Baker, S. J.
(2000). The Splicing Factor U1C Represses EWS/FLI-mediated Transactivation. J. Biol. Chem.
275: 24865-24871
[Abstract]
[Full Text]
-
Li, K. K. C., Lee, K. A. W.
(2000). Transcriptional Activation by the Ewing's Sarcoma (EWS) Oncogene Can Be Cis-repressed by the EWS RNA-binding Domain. J. Biol. Chem.
275: 23053-23058
[Abstract]
[Full Text]
-
Yang, L., Chansky, H. A., Hickstein, D. D.
(2000). EWS{middle dot}Fli-1 Fusion Protein Interacts with Hyperphosphorylated RNA Polymerase II and Interferes with Serine-Arginine Protein-mediated RNA Splicing. J. Biol. Chem.
275: 37612-37618
[Abstract]
[Full Text]
-
Lerga, A., Hallier, M., Delva, L., Orvain, C., Gallais, I., Marie, J., Moreau-Gachelin, F.
(2001). Identification of an RNA Binding Specificity for the Potential Splicing Factor TLS. J. Biol. Chem.
276: 6807-6816
[Abstract]
[Full Text]
-
Uranishi, H., Tetsuka, T., Yamashita, M., Asamitsu, K., Shimizu, M., Itoh, M., Okamoto, T.
(2001). Involvement of the Pro-oncoprotein TLS (Translocated in Liposarcoma) in Nuclear Factor-kappa B p65-mediated Transcription as a Coactivator. J. Biol. Chem.
276: 13395-13401
[Abstract]
[Full Text]
-
Belyanskaya, L. L., Gehrig, P. M., Gehring, H.
(2001). Exposure on Cell Surface and Extensive Arginine Methylation of Ewing Sarcoma (EWS) Protein. J. Biol. Chem.
276: 18681-18687
[Abstract]
[Full Text]
-
KIM, J., PELLETIER, J.
(1999). Molecular genetics of chromosome translocations involving EWS and related family members. Physiol. Genomics
1: 127-138
[Abstract]
[Full Text]